
Research compounds
NAD+
NAD+ (nicotinamide adenine dinucleotide) is an endogenous coenzyme, not a peptide. It is central to cellular energy metabolism, and tissue NAD+ levels have been reported to decline with age in rodents and humans.
- Container
- Glass vial, crimp seal, flip-top cap
- Storage
- -20 °C, desiccated, protect from light
- Paperwork
- Lot certificate (HPLC + mass spec) shown before you pay
Lot certificates
You’ll see American Peptides on the lab’s copy. They’re our supplier.
- 500 mg, lot NAD500-0803: 99.78% purity (RP-HPLC), 503.42 mg measured, identity confirmed by mass spec. Issued 2026-08-28 by Bioviridian Inc.. Verify certificate COA7592
- 1000 mg, lot NAD1000-0803: 99.74% purity (RP-HPLC), 1004.23 mg measured, identity confirmed by mass spec. Issued 2026-08-28 by Bioviridian Inc.. Verify certificate COA7611
Our vials are filled from lots made by our supplier, American Peptides, and tested by Bioviridian Inc.The laboratory’s original certificate lists American Peptides as the vendor. Look up the code at bioviridians.com to check it.
What researchers study it for
- Cellular redox and energy metabolism
- Sirtuin, PARP, and CD38 biology
- Age-related NAD+ decline
- NAD+ precursors in human trials
- Muscle and vascular function in older adults
How it is thought to work
NAD+ acts as a coenzyme that carries electrons in redox reactions of energy metabolism. It is also consumed as a substrate by non-redox enzymes including sirtuins, poly(ADP-ribose) polymerases (PARPs), and CD38, linking it to DNA repair, chromatin regulation, and immune cell function. Many human studies of raising NAD+ have used oral precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) rather than NAD+ itself.
Where the research stands
Endogenous metabolite; investigational. NAD+ is not an FDA-approved drug for any indication, and small randomized trials of precursors show raised NAD+ metabolites but mixed functional results, including no significant muscle benefit in a 2025 meta-analysis of older adults.
Sources
- Covarrubias AJ, Perrone R, Grozio A, Verdin E (2021). NAD(+) metabolism and its roles in cellular processes during ageing.. Nature Reviews Molecular Cell Biology.
- Rajman L, Chwalek K, Sinclair DA (2018). Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence.. Cell Metabolism.
- Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, Chonchol M, Seals DR (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults.. Nature Communications.
- Prokopidis K, Moriarty F, Bahat G, McLean J, Church DD, Patel HP (2025). The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis.. Journal of Cachexia, Sarcopenia and Muscle.
Read more
For laboratory research use only. Not a drug, food, supplement or cosmetic; not for human or veterinary use. Nothing on this page is medical advice or a usage guide.
